Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981748 | 1.00 | BTK (0.39) | BTKPBKKAT8SUV39H2LRRK2 | |
| SCHEMBL984226 | 0.90 | LRRK2 (0.40) | BTKLRRK2RIPK2PDE4B | |
| SCHEMBL984012 | 0.90 | USP30 (0.41) | BTKSCN9A | |
| SCHEMBL983983 | 0.89 | BTK (0.43) | BTKLRRK2RIPK2PDE4B | |
| SCHEMBL983483 | 0.89 | BTK (0.35) | BTKLRRK2RIPK2PDE4B | |
| SCHEMBL985408 | 0.89 | BTK (0.40) | BTKPBKKAT8ACACB | |
| SCHEMBL983677 | 0.89 | BTK (0.40) | BTKPBKKAT8ACACB | |
| SCHEMBL983676 | 0.89 | BTK (0.40) | BTKPBKKAT8ACACB | |
| SCHEMBL985437 | 0.88 | BTK (0.37) | BTKLRRK2ACACBRIPK2PDE4B | |
| SCHEMBL983632 | 0.88 | BTK (0.39) | BTKPBKKAT8ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | BTK 1977/4885PBK 4836/4885KAT8 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.